Two-Year Probability of Remaining Free from Severe Events (Hospitalization or Death) According to the Feeding Group and Pediatric HIV Status

<p>ANRS 1201/1202 Ditrame Plus study, Abidjan, Côte d'Ivoire, 2001–2005 (<i>n</i> = 557).</p

Two-Year Probability of Remaining Free from Adverse Health Outcome (Hospitalization or Death or Validated Morbidity) According to the Feeding Group and Pediatric HIV Status

<p>ANRS 1201/1202 Ditrame Plus study, Abidjan, Côte d'Ivoire, 2001–2005 (<i>n</i> = 557).</p

Two-Year Probability of Remaining Free from Validated Morbidity (Diarrhea, Acute Respiratory Infection, or Malnutrition) According to the Feeding Group and Pediatric HIV Status

<p>ANRS 1201/1202 Ditrame Plus Study, Abidjan, Côte d'Ivoire, 2001–2005 (<i>n</i> = 557).</p

Estimated cumulative transmission risk (CTR) and 95% confidence interval (CI) of HIV-1 infection diagnosis at age 18 months in live-born children.

<p>ANRS 1201/1202 Ditrame-Plus and ANRS 049a DITRAME cohorts, Abidjan, Côte d'Ivoire, 2001–2005. Turnbull estimates and Kaplan-Meier estimates.</p><p>I/n: number of children infected/number of children at risk for mother-to-child transmission.</p>*<p>ART = antiretroviral therapy if WHO clinical stage 4 or WHO clinical stage 3 and CD4<350/mm³ or WHO clinical stage 1/2 and CD4<200/mm³.</p>**<p>Two children were not classified for infant feeding modality. † Confidence interval based on Kaplan-Meier estimates.</p

Number of women and children by peri-partum short-course (sc) antiretroviral regimen and infant-feeding modality for prevention of Mother-To-Child transmission (PMTCT) of HIV.

<p>ANRS 1201/1202 Ditrame-Plus and ANRS 049a DITRAME cohorts, Abidjan, Côte d'Ivoire.</p><p>ZDV = short-course zidovudine; sdNVP = single-dose nevirapine during labour; 3TC = lamivudine.</p>*<p>Eight formula-fed children were excluded.</p>**<p>Two children were not classified for infant feeding modality.</p

Determinants of 18-month HIV-1 infection or death (Multivariate Cox proportional hazard model, reference: ZDV+sdNVP).

<p>ANRS 1201/1202 Ditrame-Plus, 2001–2005, Abidjan, Côte d'Ivoire.</p><p>*Variables with p<0.25 in the comparison of the three treatment groups (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001645#pone-0001645-t002" target="_blank">table 2</a>). ^§Estimated cumulative transmission risk (CTR) of HIV or death at 18 months using Kaplan-Meier estimates (%). ^§§logrank test; ^#univariate analysis = unadjusted Cox proportional hazards model; CI confidence interval; HR hazard ratio; HRa adjusted Hazard Ratio; 3TC = lamivudine; NVPsd = single-dose nevirapine during labour; ZDV  = zidovudine. HAART = highly active antiretroviral therapy if WHO clinical stage 4 or WHO clinical stage 3 and CD4<350/mm³ or WHO clinical stage 1/2 and CD4<200/mm³. #in the adjusted analysis, this variable took into account both the treatment duration and the antiretroviral regimen used.</p

Determinants of 18-month HIV-1 infection or death (Cox proportional hazard model; reference: ZDV long-term breastfed).

<p>ANRS 1201/1202 Ditrame-Plus and ANRS 049a DITRAME cohorts, Abidjan, Côte d'Ivoire.</p><p>*Variables with p<0.25 in the comparison of the three treatment groups (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0001645#pone-0001645-t002" target="_blank">table 2</a>). ^§Estimated cumulative transmission risk (CTR) of HIV-1 infection at 18-month using Kaplan-Meier estimates. ^§§Log-rank test; CI: confidence interval; ^#univariate = unadjusted Cox proportional hazards model; HR: hazard ratio; HRa: adjusted Hazard Ratio; 3TC = lamivudine; sdNVP = single-dose nevirapine during labour; ZDV  = zidovudine. ART = highly active antiretroviral therapy if WHO clinical stage 4 or WHO clinical stage 3 and CD4<350 /mm³ or WHO clinical stage 1/2 and CD4<200/mm³. #in the adjusted analysis, this variable took into account both the treatment duration and the antiretroviral regimen used.</p